Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
Company profile
Ticker
FTSV
Exchange
Website
CEO
Mark A. McCamish
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
FTSV stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
17 Apr 20
EFFECT
Notice of effectiveness
8 Apr 20
25-NSE
Exchange delisting
7 Apr 20
POSASR
Automatic shelf registration (post-effective amendment)
7 Apr 20
POS AM
Prospectus update (post-effective amendment)
7 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Apr 20
8-K
Completion of Acquisition or Disposition of Assets
7 Apr 20
SC TO-T/A
Third party tender offer statement (amended)
7 Apr 20
SC 14D9/A
Tender offer solicitation (amended)
7 Apr 20
Latest ownership filings
Institutional ownership, Q1 2022
1.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 496.77 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lightspeed Venture Partners X | 496.77 k | $0.00 |